AstraZeneca/Amgen Imfinzi–Imdelltra combo improves survival goal
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial, meeting its main survival goal.
AstraZeneca said on Tuesday that its cancer drug Imfinzi, when combined with Amgen's targeted immunotherapy Imdelltra, significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.